View of Samsung Biologics' Plant 4 in Songdo, Incheon. /Courtesy of Samsung Biologics

Samsung Biologics has announced its first order achievement of 2025 by securing a contract worth 2 trillion won.

On the 14th, Samsung Biologics disclosed that it signed a contract for contract manufacturing (CMO) valued at $1.41011 billion (approximately 2.747 trillion won) with a European pharmaceutical company. The contract period extends until December 31, 2030, and the customer and product names remain confidential due to non-disclosure agreements.

This contract is the largest in the company's history since its founding and is about 40% of last year’s total order amount (5.4035 trillion won). The agreement has also set a new record for the company's highest order amount.

With consecutive contract acquisitions and increased performance, evaluations indicate that it is strengthening its position as a global contract development and manufacturing organization (CDMO). Samsung Biologics has surpassed a cumulative total of $17.6 billion in orders since its establishment. Last year, the company consecutively signed three large contracts, each worth 1 trillion won, in major global markets including the U.S., Europe, and Asia. The total order amount last year reached a record high of 5.4035 trillion won, an increase of approximately 1.5 times compared to the previous year.

The company noted, "We currently have secured 17 out of the top 20 global pharmaceutical companies as clients," adding, "This is the result of our overwhelming production capacity, quality competitiveness, and numerous track records that form our core order competitiveness."

Samsung Biologics is expanding its production capacity to meet the growing demand for biopharmaceuticals. The fifth plant, which will be a 180,000-liter facility that incorporates optimal cases from the first to fourth plants, is under construction with a target to start operations in April. Once completed, Samsung Biologics will secure a total production capacity of 784,000 liters. According to the company, it has recorded a batch success rate of 99%, demonstrating its competitiveness throughout the entire pharmaceutical manufacturing and management process.

As of December 2024, it has obtained a total of 340 manufacturing approvals from global regulatory agencies, including 41 from the U.S. Food and Drug Administration (FDA) and 36 from the European Medicines Agency (EMA). As production capacity increases and orders grow, the number of approvals has also increased each year. The success rate for passing inspections by regulatory agencies remains at the highest level in the industry.

Meanwhile, Samsung Biologics is strengthening its business activities by participating in large-scale pharmaceutical and biopharmaceutical industry conferences held in the U.S., Europe, and Asia. In particular, it is focusing on strengthening networking for business expansion by attending the "2025 J.P. Morgan Healthcare Conference (JPMHC)," the largest investment event in the pharmaceutical and biopharmaceutical industry, which is currently ongoing from the 13th to the 16th (local time) in San Francisco, where it is meeting with investors and potential clients.